DelveInsight’s “Nausea and Vomiting Induced by Motion Sickness Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Nausea and Vomiting Induced by Motion Sickness, historical and forecasted epidemiology as well as the Nausea and Vomiting Induced by Motion Sickness market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

The latest healthcare forecast report provides an in-depth analysis of Nausea and Vomiting Induced by Motion Sickness, offering comprehensive insights into the Nausea and Vomiting Induced by Motion Sickness revenue trends, prevalence, and treatment landscape. The report delves into key Nausea and Vomiting Induced by Motion Sickness statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Nausea and Vomiting Induced by Motion Sickness therapies. Additionally, we cover the landscape of Nausea and Vomiting Induced by Motion Sickness clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Nausea and Vomiting Induced by Motion Sickness treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Nausea and Vomiting Induced by Motion Sickness space.

To Know in detail about the Nausea and Vomiting Induced by Motion Sickness market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Nausea and Vomiting Induced by Motion Sickness Market Forecast

Some of the key facts of the Nausea and Vomiting Induced by Motion Sickness Market Report: 

• The Nausea and Vomiting Induced by Motion Sickness market size was valued ~USD 796 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2019-2032)

• In May 2024, Vanda Pharmaceuticals has announced positive results from its second Phase III clinical trial of tradipitant for treating motion sickness. Named Motion Serifos, the double-blind, randomized, multicenter, placebo-controlled trial included 316 participants with a history of motion sickness.

• DelveInsight’s estimates indicate that, among the 7MM, the US held the largest market share for nausea and vomiting induced by motion sickness, generating nearly USD 526.32 million in revenue in 2022. This is expected to grow over the forecast period due to a rising population and the introduction of new therapies.

• Japan held the second largest market share for nausea and vomiting caused by motion sickness among the 7MM, generating around USD 95.06 million in revenue in 2022, with changes anticipated over the forecast period.

• Vanda Pharmaceuticals and Eli Lilly’s VLY-686 (tradipitant) is a small molecule NK-1 receptor antagonist designed to prevent vomiting. It is expected to enter the US market by 2025, with projected revenue of USD 0.77 million in its first year.

• Key Nausea and Vomiting Induced by Motion Sickness Companies: Defender Pharmaceuticals, Vanda Pharmaceuticals, Eli Lilly, and others.

• Key Nausea and Vomiting Induced by Motion Sickness Therapies: DPI-386 (scopolamine gel), VLY-686 (tradipitant), and others.

• The Nausea and Vomiting Induced by Motion Sickness market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Nausea and Vomiting Induced by Motion Sickness pipeline products will significantly revolutionize the Nausea and Vomiting Induced by Motion Sickness market dynamics.

• In 2022, there were around 217.2 million total cases of motion sickness across the 7MM, and this number is expected to rise by 2032.

• In 2022, the US had the highest number of motion sickness cases among the 7MM, making up approximately 52% of the total, while Japan had the fewest cases, contributing about 14% of the overall count.

• In 2022, among the EU4 and the UK, France reported the highest number of motion sickness cases, with approximately 17.1 million cases, followed by the UK with 16.9 million cases. Spain had the fewest cases, totaling around 11.8 million.

• In the US, motion sickness was most commonly caused by car and bus travel, each with 33.7 million cases in 2022. This was followed by train travel with 22.5 million cases, air travel with 16.9 million cases, and other modes. These figures are expected to rise by 2032.

• In the EU4 and the UK, approximately 30% of motion sickness cases in 2022 were attributed to car and bus travel for each mode, followed by around 20% of cases from train travel, 15% from airplane travel, and 5% from boat or ship travel.

Nausea and Vomiting Induced by Motion Sickness Overview

Nausea and vomiting induced by motion sickness are symptoms triggered by repeated motion, such as during travel by car, boat, or plane. Motion sickness occurs when there is a disconnect between sensory signals from the inner ear, eyes, and body, causing the brain to misinterpret motion. This results in symptoms like dizziness, nausea, vomiting, cold sweats, and fatigue. Treatments and preventive measures include medications, such as antihistamines, as well as non-drug methods like acupressure bands and focusing on stable objects outside the vehicle.

Get a Free sample for the Nausea and Vomiting Induced by Motion Sickness Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/nausea-and-vomiting-induced-by-motion-sickness-market

Nausea and Vomiting Induced by Motion Sickness Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Nausea and Vomiting Induced by Motion Sickness Epidemiology Segmentation:

The Nausea and Vomiting Induced by Motion Sickness market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Nausea and Vomiting Induced by Motion Sickness

• Prevalent Cases of Nausea and Vomiting Induced by Motion Sickness by severity

• Gender-specific Prevalence of Nausea and Vomiting Induced by Motion Sickness

• Diagnosed Cases of Episodic and Chronic Nausea and Vomiting Induced by Motion Sickness

Download the report to understand which factors are driving Nausea and Vomiting Induced by Motion Sickness epidemiology trends @ Nausea and Vomiting Induced by Motion Sickness Epidemiology Forecast

Nausea and Vomiting Induced by Motion Sickness Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Nausea and Vomiting Induced by Motion Sickness market or expected to get launched during the study period. The analysis covers Nausea and Vomiting Induced by Motion Sickness market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Nausea and Vomiting Induced by Motion Sickness Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Nausea and Vomiting Induced by Motion Sickness Therapies and Key Companies

• DPI-386 (scopolamine gel): Defender Pharmaceuticals

• VLY-686 (tradipitant): Vanda Pharmaceuticals/Eli Lilly

Discover more about therapies set to grab major Nausea and Vomiting Induced by Motion Sickness market share @ Nausea and Vomiting Induced by Motion Sickness Treatment Landscape

Nausea and Vomiting Induced by Motion Sickness Market Drivers

• Increasing Travel Frequency

• Advancements in Treatment Options

• Rising Awareness

• Growing Tourism and Leisure Activities

Nausea and Vomiting Induced by Motion Sickness Market Barriers

• Side Effects of Existing Treatments

• Lack of Awareness in Rural Areas

• Seasonal Variations in Demand

• Competition from Non-Pharmaceutical Remedies

Scope of the Nausea and Vomiting Induced by Motion Sickness Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Nausea and Vomiting Induced by Motion Sickness Companies: Defender Pharmaceuticals, Vanda Pharmaceuticals, Eli Lilly, and others

• Key Nausea and Vomiting Induced by Motion Sickness Therapies: DPI-386 (scopolamine gel), VLY-686 (tradipitant), and others

• Nausea and Vomiting Induced by Motion Sickness Therapeutic Assessment: Nausea and Vomiting Induced by Motion Sickness current marketed and Nausea and Vomiting Induced by Motion Sickness emerging therapies

• Nausea and Vomiting Induced by Motion Sickness Market Dynamics: Nausea and Vomiting Induced by Motion Sickness market drivers and Nausea and Vomiting Induced by Motion Sickness market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Nausea and Vomiting Induced by Motion Sickness Unmet Needs, KOL’s views, Analyst’s views, Nausea and Vomiting Induced by Motion Sickness Market Access and Reimbursement 

To know more about Nausea and Vomiting Induced by Motion Sickness companies working in the treatment market, visit @ Nausea and Vomiting Induced by Motion Sickness Clinical Trials and Therapeutic Assessment

Table of Contents 

1. Nausea and Vomiting Induced by Motion Sickness Market Report Introduction

2. Executive Summary for Nausea and Vomiting Induced by Motion Sickness

3. SWOT analysis of Nausea and Vomiting Induced by Motion Sickness

4. Nausea and Vomiting Induced by Motion Sickness Patient Share (%) Overview at a Glance

5. Nausea and Vomiting Induced by Motion Sickness Market Overview at a Glance

6. Nausea and Vomiting Induced by Motion Sickness Disease Background and Overview

7. Nausea and Vomiting Induced by Motion Sickness Epidemiology and Patient Population

8. Country-Specific Patient Population of Nausea and Vomiting Induced by Motion Sickness 

9. Nausea and Vomiting Induced by Motion Sickness Current Treatment and Medical Practices

10. Nausea and Vomiting Induced by Motion Sickness Unmet Needs

11. Nausea and Vomiting Induced by Motion Sickness Emerging Therapies

12. Nausea and Vomiting Induced by Motion Sickness Market Outlook

13. Country-Wise Nausea and Vomiting Induced by Motion Sickness Market Analysis (2019–2032)

14. Nausea and Vomiting Induced by Motion Sickness Market Access and Reimbursement of Therapies

15. Nausea and Vomiting Induced by Motion Sickness Market Drivers

16. Nausea and Vomiting Induced by Motion Sickness Market Barriers

17.  Nausea and Vomiting Induced by Motion Sickness Appendix

18. Nausea and Vomiting Induced by Motion Sickness Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/